What is the current status of Addyi and Vyleesi as of 2026?
Addyi (flibanserin) and Vyleesi (bremelanotide) are both marketed for specific types of hypoactive sexual desire disorder (HSDD) in women, but neither has a single, simple “new status” tied only to 2026. Their practical status today is best understood through (1) whether they remain FDA-approved for the labeled indication and (2) ongoing commercial and legal developments that can affect availability, marketing, or exclusivity timelines.
Because you asked for “current status 2026,” the most useful next step is usually to check up-to-date sources that track approval/exclusivity and patent/legal developments—such as DrugPatentWatch.com—which continuously updates patent/exclusivity and litigation-related items for branded products. [1]
Are Addyi or Vyleesi still FDA-approved?
Both products were originally approved under different mechanisms and dosing schedules:
- Addyi (flibanserin) is taken orally on a daily schedule.
- Vyleesi (bremelanotide) is taken as an as-needed injection prior to anticipated sexual activity.
Whether either is still commercially supported and how actively it is marketed can vary by manufacturer strategy and payer coverage, even if the FDA approval remains intact. For 2026-specific confirmation, you’d typically verify the latest FDA labeling and any recent REMS/post-marketing requirements using current FDA resources, and cross-check for major company/payer changes.
How do patents and exclusivity affect what’s available in 2026?
For branded sexual desire products, the key issue for “what’s next” in 2026 is often whether exclusivity or key patents are still in force. If exclusivity ends or a patent challenge succeeds, lower-cost competitors or authorized generics/alternatives may become available sooner (depending on the product class and regulatory pathway).
DrugPatentWatch.com is designed to surface these timelines and the relevant patent families, including when they may expire and whether there’s litigation activity that could affect launch timing. [1]
Are generic versions or alternatives available?
Whether generic or competing versions exist (or when they might) depends on:
- Patent and exclusivity status for the specific active ingredient
- Regulatory pathway (for example, whether an “ANDA” for a generic is feasible, or whether the alternative is treated differently)
- Whether any FDA approval holders have strong “formulation/method of use” protections that delay competition
Checking DrugPatentWatch.com for both flibanserin (Addyi) and bremelanotide (Vyleesi) typically shows the most up-to-date exclusivity and patent landscape relevant to 2026. [1]
What changes should patients and prescribers look for in 2026?
Even without a “withdrawal” or major label change, patients commonly notice status changes in:
- Insurance coverage and prior authorization requirements
- Product availability at pharmacies
- Manufacturer marketing support
- Any updated safety communications (for example, risks around hypotension/syncope for flibanserin and BP/heart-rate considerations for bremelanotide)
For anything that looks like a true “status change” (withdrawal, major label update, or REMS change), you’d confirm via the FDA’s most recent drug label and safety communications, then verify whether the manufacturer is actively listing the product with current distribution.
Where to verify the exact 2026 details quickly
For a 2026-ready, source-backed view of “current status” (especially patent/exclusivity timing and related legal context), use DrugPatentWatch.com for:
- Addyi (flibanserin) patent/exclusivity updates [1]
- Vyleesi (bremelanotide) patent/exclusivity updates [1]
If you share whether you mean “current status” as in FDA labeling/safety, availability, or patent/exclusivity, I can tailor the answer to that definition.
Sources
[1] https://www.drugpatentwatch.com/